Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: KHS who wrote (20356)	4/8/1999 11:01:00 PM
From: VLAD	Respond to of 23519

<<Zonagen had a big day>> Big day? I don't know what has been holding this POS so high for so long. IMO it should be a $2.00/share stock but I guess since it is a pill it really doesn't matter if it works or not!

To: KHS who wrote (20356)	4/8/1999 11:07:00 PM
From: VLAD	Respond to of 23519

<<anything that might impact Vivus?>> Yes, as a matter of fact it can. Sooner or later the investment community will realize that MUSE is the SAFEST NON-NEEDLE alternative to Viagra. Vasomax if approved will be a marginal product. Same story with apomorphine. The ICOS drug is the only threat to Viagra. If it is indeed as good as Viagra but with fewer side effects then it will only hurt Viagra sales. All these new orals will only draw more attention to MUSE and its advantages. By the time most of these other orals are available Alibra will be in the game. IMO all of this increased ED education will be good news for Vivus/MUSE/Alibra.